Suzhou Tianma Pharma Group Tianji Bio-Pharmaceutical Co., Ltd.
Suzhou Tianma Pharma Group Tianji Bio-Pharmaceutical Co., Ltd. is a peptide manufacturer based in China. Direct manufacturer. Founded 2000. Holds US DMFs for semaglutide, tirzepatide, liraglutide, degarelix and 4 more API.
Listing reviewed September 2026.
About Suzhou Tianma Pharma Group Tianji Bio-Pharmaceutical Co., Ltd.
Chinese contract manufacturer of pharmaceutical APIs, formulations, and peptides. Founded in 2000, based in Suzhou, China. Specializes in peptide-related chemicals including Thymalfasin, Terlipressin, Carbetocin, Semaglutide, and custom peptide synthesis services. Part of Suzhou Tianma Pharma Group, one of the leading companies in the domestic peptide industry.
Directory assessment: Suzhou Tianma Pharma Group Tianji Bio-Pharmaceutical Co., Ltd. is listed as a manufacturer in the peptide supply chain, serving Asia markets from China. As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. This profile lists 2 sources for reference. This supplier has a strong confidence score, indicating a high level of verification and reliability for B2B sourcing.
- Degarelix: DMF 43215 (Type II, active), submitted 2025-12-16
- Difelikefalin: DMF 44779 (Type II, active), submitted 2026-09-17
- Linaclotide: DMF 42635 (Type II, active), submitted 2025-09-23
- Liraglutide: DMF 43515 (Type II, active), submitted 2026-02-09
- Octreotide: DMF 44547 (Type II, active), submitted 2026-08-06
- Semaglutide: DMF 38213 (Type II, active), submitted 2023-03-27
- Thymalfasin: DMF 44294 (Type II, active), submitted 2026-06-29
- Tirzepatide: DMF 44306 (Type II, active), submitted 2026-06-29
DMF numbers from the FDA quarterly DMF list. A filed DMF is not FDA approval; its contents are confidential. Reviewed 2026-10-23.